2023年6月4日,

髓治疗,临床分期mRNA-immunotherapy公司——宣布完成了7300万美元的资金由Hatteras新投资者的投资合作伙伴参与拱Venture Partners和摩尔的战略投资。所有现有的投资者,包括Newpath伙伴,8风险投资,风险投资,和亚历山大也参加了。所得资金将支持继续mt - 101的临床发展,骨髓的细胞疗法项目阶段1/2 T细胞淋巴瘤,并将加快发展mt - 302,一个first-in-class TROP2-FcA mRNA-LNP产品,为TROP2-expressing肿瘤1/2研究阶段。和额外的体内编程候选人也推进诊所。mt - 302:从公司的专有ATAK汽车受体图书馆,骨髓的小说体内工程平台具体目标和激活骨髓细胞引起更广泛的抗肿瘤获得性免疫。通过这种方法,骨髓表明交付lipid-nanoparticles (lnp)封装mRNA的结果由髓细胞体内吸收和选择性表达,导致有效的肿瘤死亡在多个冷肿瘤模型。公司的领导体内程序mt - 302是一个TROP2-targeting体内骨髓内舱车专为表达式。和TROP2肿瘤相关抗原表达广泛上皮肿瘤,包括一些最难治性癌症。mt - 302表明单一疗法治疗活动TROP2 / TNBC模型,确定程序的效力髓细胞在T细胞的缺失。骨髓相信mt - 302 TROP2-ADC方法相比有明显优势通过其进行完整的免疫反应的能力。 In 2023, Myeloid expects to initiate a Phase 1/2 clinical study with MT-302 for patients with TROP2-expressing tumors. MT-101: MT-101 is the company’s first autologous CAR monocyte. And this candidate was derived from the Company’s proprietary ATAK platform and designed to harness the ability of myeloid cells to penetrate into tumors and promote broad anti-tumor activity. Plus MT-101 targets CD5, a surface receptor that is present in greater than 75% of peripheral T cell lymphomas. To create MT-101, the patient’s cells are engineered ex vivo with the mRNA-strand coding for the CAR. The engineered cells are delivered back to the patient within a vein-to-vein time of eight days. The ATAK CAR is proprietary to Myeloid and manufactured using the Company’s patented processes. The IMAGINE study (NCT05138458) is a Phase 1/2, multicenter, open-label, first-in-human, multiple ascending dose study to evaluate MT-101 in patients with refractory or relapsed PTCL and CTCL. The dose-escalation portion of this study, conducted with and without conditioning therapy, is open and enrolling patients. RetroT: Retrotransposons are genetic elements that replicate through reverse transcription of an RNA transposition intermediate. And retrotransposons contribute to structural changes and more importantly, to gene regulation. Myeloid’s RetroT technology relies on a single-strand mRNA to deliver genetic sequences and integration enzymes. This breakthrough technology offers the potential to deliver gene-sized pieces of DNA into the genome in a virus-free manner. And the payload realizable with RetroT is larger than currently possible with all known existing gene editing technologies. As a result, the company’s RetroT platform holds the potential to significantly expand the type and scope of genetic errors that can be reversed in situ. In March 2022, Myeloid entered into an exclusive option and research collaboration agreement with Prime Medicine to develop and accelerate RetroT. KEY QUOTES: “Myeloid continues to make significant progress across all aspects of our business. We are pioneering the convergence of immunology and RNA science to build a clinical-stage portfolio of products, starting with the significant unmet needs of cancer patients. We are pleased that such high-quality investors have joined with us to accelerate this effort.” — Daniel Getts, Ph.D., Chief Executive Officer of Myeloid “Hatteras focuses on investments in cutting-edge companies that are disrupting the status quo and accelerating the pace of innovation. We are highly encouraged by the innovation, execution and clinical development progress demonstrated by Myeloid. We are proud to support this field-leading Company through its next phase of growth and are optimistic that these approaches will drive a meaningful clinical outcome for patients.” — Clay B. Thorp, General Partner at Hatteras Trending on Pulse 2.0